Results 41 to 50 of about 84,209 (281)

Targeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug Development

Current Oncology
Non-small cell lung cancer (NSCLC) remains a major contributor to cancer-related deaths worldwide, with therapeutic resistance presenting a critical clinical hurdle.
Xue Gong, Yongzhao Zhou, Yi Deng
doaj   +1 more source

The science of clinical practice: disease diagnosis or patient prognosis? Evidence about "what is likely to happen" should shape clinical practice. [PDF]

, 2015
BACKGROUND: Diagnosis is the traditional basis for decision-making in clinical practice. Evidence is often lacking about future benefits and harms of these decisions for patients diagnosed with and without disease.
A Chauffard, A Vickers, AD Hingorani, Adam Timmis, AJ Vickers, Alastair D Hay, C Mar Del, CK Lee, DA Asch, Danielle A Van Der Windt, DE Newby, Douglas G Altman, E Rosenberg Charles, E Stolper, EAM Gale, EW Steyerberg, G-J Dinant, George Peat, H Downing, H Hemingway, Harry Hemingway, HG Welch, HM Krumholz, I Roberts, Ian Roberts, Independent UK Panel on Breast Cancer Screening, J Vestbo, J Wellwood, JC Hill, JG Jarvik, Jonathan J Deeks, Jutel Annemarie Goldstein, Kate M Dunn, L Ferrante di Ruffano, Linda LeResche, M Korff Von, M Roland, Michael Sharpe, Michael Von Korff, O Bruder, P Brown, Pablo Perel, PD White, Peter Croft, PM Bossuyt, R Aronowitz, R Moynihan, R Smith-Bindman, RA Aronowitz, Richard D Riley, Richard J Stevens, RK Simmons, RO Bonow, SJ Lord, SS Watson, Steffen E Petersen, TB Murdoch, WJ Katon   +57 more
core   +4 more sources

Identification of Mannose‐Capped‐Arabinomannan 101‐mer as a Potential Influenza Virus Vaccine Adjuvant

Advanced Science, EarlyView.
Well‐defined and synthetic mannose‐capped arabinomannan 101‐mer from Mycobacterium tuberculosis cell wall was identified as a potent influenza vaccine adjuvant, boosting the antibody response, realizing full protection and showing excellent safety. ABSTRACT Many natural bacterial components as adjuvants can activate the host immune system, but the ...
Yu‐Fang Zhang, Ruihong Xu, Jia Luo, Yuxin Ma, Guozhi Xiao, Ye Liu   +5 more
wiley   +1 more source

Determinants of the onset and development of multimorbidity in different subpopulations of older Chinese adults: insights from the China Health and Retirement Longitudinal Study

Annals of Medicine
Background and objectives Multimorbidity trajectories help to analyze the onset and development of multimorbidity over time and are an important public health matter.
Changcong Wang, Shutong Wang, Haitao Yu, Xinyue Zhang, Meng Zhang, Dongmei Mu   +5 more
doaj   +1 more source

Sex-specific patterns and lifetime risk of multimorbidity in the general population: a 23-year prospective cohort study

BMC Medicine, 2022
Background Multimorbidity poses a major challenge for care coordination. However, data on what non-communicable diseases lead to multimorbidity, and whether the lifetime risk differs between men and women are lacking.
Premysl Velek, Annemarie I. Luik, Guy G. O. Brusselle, Bruno Ch. Stricker, Patrick J. E. Bindels, Maryam Kavousi, Brenda C. T. Kieboom, Trudy Voortman, Rikje Ruiter, M. Arfan Ikram, M. Kamran Ikram, Evelien I. T. de Schepper, Silvan Licher   +12 more
doaj   +1 more source

'Learning together': Sharing international experience on new models of primary care [PDF]

, 2018
No abstract ...
Blane, David N., Gillies, John C.M., Mercer, Stewart W., Smith, Gregor I.   +3 more
core   +1 more source

Inactivation Rap2a in Endothelial Cell Prevents Pulmonary Fibrosis by Regulating Immune Microenvironment Through MAP4K4‐VCAM1 Signaling

Advanced Science, EarlyView.
We identified the endothelial RAP2A as a regulator of inflammatory endothelial activation in experimental lung fibrosis and suggest that targeting RAP2A‐mediated signaling may represent a potential strategy to modulate endothelial–immune crosstalk during fibrotic lung injury.
Xiaolan Zheng, Peng Yue, Kaiyu Zhou, Guidong Gong, Yue Zhang, Sha Lin, Xu Liu, Yanjiang Zheng, Siyuan Jing, Junling Guo, Yan Qi, Bi‐Sen Ding, Yimin Hua, Yifei Li   +13 more
wiley   +1 more source

Temporal change in multimorbidity prevalence, clustering patterns, and the association with mortality: findings from the China Kadoorie Biobank study in Jiangsu Province

Frontiers in Public Health
ObjectivesThe characteristics of multimorbidity in the Chinese population are currently unclear. We aimed to determine the temporal change in multimorbidity prevalence, clustering patterns, and the association of multimorbidity with mortality from all ...
Hao Yu, Hao Yu, Ran Tao, Jinyi Zhou, Jian Su, Yan Lu, Yujie Hua, Jianrong Jin, Pei Pei, Canqing Yu, Canqing Yu, Canqing Yu, Dianjianyi Sun, Dianjianyi Sun, Dianjianyi Sun, Zhengming Chen, Liming Li, Liming Li, Liming Li, Jun Lv, Jun Lv, Jun Lv   +21 more
doaj   +1 more source

The burden of disease-specific multimorbidity among older adults in India and its states: evidence from LASI

BMC Geriatrics, 2023
Background Around the world, advances in public health and changes in clinical interventions have resulted in increased life expectancy. Multimorbidity is becoming more of an issue, particularly in countries where the population is rapidly ageing.
Priyanka Patel, T. Muhammad, Harihar Sahoo   +2 more
doaj   +1 more source

Multimorbidity and complex multimorbidity in Brazilian rural workers

PLOS ONE, 2019
To estimate the prevalence of multimorbidity and complex multimorbidity in rural workers and their association with sociodemographic characteristics, occupational contact with pesticides, lifestyle and clinical condition.This is a cross-sectional epidemiological study with 806 farmers from the main agricultural municipality of the state of Espírito ...
Glenda Blaser Petarli, Monica Cattafesta, Monike Moreto Sant’Anna, Olívia Maria de Paula Alves Bezerra, Eliana Zandonade, Luciane Bresciani Salaroli   +5 more
openaire   +4 more sources